Summary of Key Points Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., plans to utilize part of its idle raised funds for cash management, with a maximum investment amount of RMB 700 million, ensuring high safety and liquidity in the investment products chosen [1][2][8]. Investment Overview - **Investment Purpose**: The aim is to maximize shareholder value by improving the efficiency of fund usage while ensuring that the use of raised funds is not affected and risks are effectively controlled [2][6]. - **Investment Amount and Duration**: The company intends to use up to RMB 700 million for cash management, with the funds being able to roll over within a 12-month period [2][5]. - **Source of Funds**: The funds are sourced from the proceeds of the company's initial public offering, which raised a total of approximately RMB 1.64 billion after deducting issuance costs [2][5]. Investment Methodology - The company will invest in high-safety, liquid financial products such as agreement deposits, structured deposits, time deposits, notice deposits, large certificates of deposit, and income certificates [1][5][6]. - The cash management products will not be used for pledging or for investment purposes in securities [5][6]. Approval Process - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 21, 2025, with a validity period of 12 months from the date of approval [2][6][8]. - The management team has been authorized to make investment decisions and sign relevant contracts, with the finance department responsible for implementation [1][6]. Opinions from Supervisory Board and Sponsor - The supervisory board supports the cash management initiative, stating it will not affect the use of raised funds or harm the interests of the company and its shareholders [7][8]. - The sponsor, Guotai Junan Securities, has confirmed that the cash management plan complies with relevant regulations and will enhance fund usage efficiency without altering the intended use of raised funds [8].

Core Viewpoint - The company has approved the formulation and revision of certain governance systems to enhance operational standards and protect shareholder rights [1][2]. Group 1: Governance System Revisions - The board of directors convened on August 21, 2025, to review and approve the proposal for governance system revisions [1]. - The revisions are in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. - The specific governance systems being established and revised include the "Market Value Management System" and the "Public Opinion Management System" [1]. Group 2: Market Value Management System - The "Market Value Management System" consists of five chapters and seventeen articles, covering basic principles, management structure, main methods, monitoring mechanisms, and emergency measures [2]. - The aim of this system is to enhance the company's market value management practices and improve investor returns [1][2]. Group 3: Public Opinion Management System - The "Public Opinion Management System" includes four chapters and sixteen articles, focusing on the organizational structure and responsibilities for managing public opinion, as well as principles and measures for handling various types of public opinion information [2]. - This system is designed to strengthen the company's ability to respond to public sentiment and establish a rapid response and emergency handling mechanism [1][2].

证券代码：688293 证券简称：奥浦迈 公告编号：2025-068 上海奥浦迈生物科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 （二）资产减值损失——存货跌价损失 根据《上海证券交易所科创板股票上市规则》《企业会计准则》等相关法律 法规的规定，为真实、准确、公允的反映上海奥浦迈生物科技股份有限公司（以 下简称"奥浦迈"或"公司"）2025年半年度的财务状况及经营情况，基于谨慎性原 则，公司对合并报表范围内截至2025年6月30日的各类资产进行减值测试，对存 在减值迹象的有关资产计提了减值准备。现将相关情况公告如下： 一、计提资产减值准备的情况概述 公司2025年半年度拟计提信用减值损失和资产减值损失共计639.11万元，具 体情况如下表： | | | 单位：万元 | 币种：人民币 | | | --- | --- | --- | --- | --- | | | 项目 | 2025 | 年半年度预计计提金额 | | | 信用减值损失 | | 应收账款坏账损失 | | 430.61 | | 资产减值损失 | | 存货跌价损失 | | 208.50 | | | 合计 | | 639.11 | | ...

Core Viewpoint - The document outlines the management system for the temporary suspension and exemption of information disclosure by Shanghai Aopumai Biotechnology Co., Ltd, ensuring compliance with relevant laws and regulations [1][2]. Group 1: General Provisions - The purpose of the system is to regulate the handling of temporary suspension and exemption of information disclosure, urging the company and related parties to fulfill their disclosure obligations in accordance with the law [1]. - The system applies to the handling of temporary suspension and exemption of information disclosure as per the Securities Law, the listing rules of the Science and Technology Innovation Board, and other relevant regulations [1][2]. Group 2: Scope of Temporary Suspension and Exemption - Information that involves trade secrets or confidential business information may be temporarily suspended or exempted from disclosure if it meets certain conditions, such as potential harm to the company or others' interests [2][3]. - If there is sufficient evidence that the information involves state secrets, it may be exempted from disclosure in accordance with the law [2][3]. Group 3: Procedures for Temporary Suspension and Exemption - The company’s board secretary is responsible for organizing and coordinating matters related to the temporary suspension and exemption of information disclosure [4]. - Relevant departments must submit written materials regarding the reasons for suspension or exemption, ensuring the accuracy and completeness of the information [4][5]. Group 4: Internal Review Process - The internal review process for temporary suspension or exemption involves submitting applications to the securities affairs department, which are then reviewed by the board secretary and approved by the chairman [6]. - If the application for suspension or exemption is not approved, the company must disclose the information in accordance with regulatory requirements [6]. Group 5: Accountability and Penalties - The company has established a mechanism for accountability regarding the temporary suspension and exemption of information disclosure, with potential penalties for those responsible for non-compliance [7]. - The company reserves the right to pursue responsibility against consultants or intermediaries who disclose company information without authorization, leading to losses [7]. Group 6: Miscellaneous Provisions - Other matters related to the temporary suspension and exemption of information disclosure must comply with the relevant rules and regulations of the Science and Technology Innovation Board and other applicable laws [9]. - The system will take effect upon approval by the company's board of directors and will be revised as necessary [9].

Summary of Key Points Core Viewpoint The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and maximize shareholder returns while ensuring compliance with regulations and maintaining the intended use of the raised funds [1][7]. Group 1: Fundraising and Management - The company raised a total of RMB 1,643,705,576.40 through its initial public offering, with a net amount after expenses being RMB 1,643,705,576.40 [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Group 2: Cash Management Plan - The company plans to use up to RMB 70,000.00 million of temporarily idle raised funds for cash management, with a rolling usage period of 12 months [3][4]. - The investment products will include safe and liquid options such as fixed deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [4]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not affect the normal operation of the fundraising projects [5][6]. - The supervisory board supports the plan, stating it will not harm the interests of the company or its shareholders [6]. Group 4: Compliance and Risk Management - The cash management activities are in compliance with relevant regulations and internal management systems, ensuring no change in the intended use of the raised funds [7]. - The company will implement strict risk control measures, focusing on high-security and high-liquidity investment products, while monitoring market conditions [5].

证券代码：688293 证券简称：奥浦迈 公告编号：2025-070 上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为36,139,446股。 ? 本次股票上市流通日期为2025 年 9 月 2 日。 一、 本次上市流通的限售股类型 年转让的公司的股份不超过本人持有的公司股份总数的百分之二十五，任期届满 离职后半年内不得转让公司股份。如本人在任期届满前离职的，在本人就任时确 定的任期内和任期届满后六个月内不得转让持有的公司股份。如上述三十六个月 锁定期满，则每年转让的公司的股份不超过本人持有的公司股份总数的百分之二 十五，但自离职之日起六个月内不转让本人持有的公司股份。上述三十六个月锁 定期满且本人在公司担任核心技术人员期间，每年转让的公司的股份不超过本人 持有的公司股份总数的百分之二十五，离职后半年内不得转让持有的公司股份。 现金红利、送股、转增股本 ...

上海奥浦迈生物科技股份有限公司 信息披露暂缓与豁免业务 管理制度 二〇二五年八月 第一章 总则 第一条 为规范上海奥浦迈生物科技股份有限公司（以下简称"公司"或 "本公司"）信息披露暂缓与豁免业务的办理，督促公司及相关信息披露义务 人（以下简称"信息披露义务人"）依法合规地履行信息披露义务，根据《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司信息披露管理 办法》《上市公司信息披露暂缓与豁免管理规定》《上海证券交易所科创板股票上 市规则》（以下简称"《科创板上市规则》"）、《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》（以下简称"《规范运作指引》"） 等法律、法规、部门规章、规范性文件及《上海奥浦迈生物科技股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，结合公司实际情况，特制 定本制度。 第二条 公司按照《证券法》《科创板上市规则》《规范运作指引》及其 他相关法律、法规、规范性文件的规定，办理信息披露暂缓、豁免业务的，适 用本制度。 第三条 信息披露义务人应当披露的信息存在《科创板上市规则》《规范 运作指引》等相关法律、法规、规范性文件及上海证券交易所其他相关业务规 ...

Core Viewpoint - Aopu Mai (688293) reported a strong performance in the first half of 2025, with significant growth in revenue and net profit, driven by ongoing client pipeline development and rapid expansion in overseas markets [1] Financial Performance - The company achieved operating revenue of 178 million yuan, representing a year-on-year increase of 23.77% [1] - The net profit attributable to shareholders reached 37.55 million yuan, marking a year-on-year growth of 55.55% [1] - Basic earnings per share were reported at 0.33 yuan [1] Dividend Distribution - The company proposed a cash dividend of 2.3 yuan per 10 shares (including tax) [1] Business Growth Drivers - Revenue growth was primarily attributed to the continuous advancement of the client pipeline and the rapid expansion of overseas business [1] - Service business also showed improvement, with overall revenue growth of 13.24% compared to the same period last year [1]

证券代码：688293 证券简称：奥浦迈 公告编号：2025-069 上海奥浦迈生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 3 日（星期三）下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 27 日（星期三）至 9 月 2 日（星期二）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@opmbiosciences.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海奥浦迈生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 23 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-064 上海奥浦迈生物科技股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行的审议程序 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）于2025 年8月21日召开第二届董事会第十一次会议、第二届监事会第十次会议，审议通 过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影 响募集资金使用，并有效控制风险的前提下，使用最高不超过人民币70,000万元 （包含本数）暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好的 投资产品（包括但不限于协定性存款、结构性存款、定期存款、通知存款、大额 存单、收益凭证等），在上述额度范围内，资金可以滚动使用，使用期限为12 个月。同时董事会授权公司管理层行使现金管理投资决策权并签署相关合同/协 议文件，具体事项由公司财务部负责组织实施。公司监事会发表了明确同意的意 见，保荐机构国泰海通证券股份有限公司（以下简称"国泰海 ...